“Winning a SPARK award means that the public recognizes the significance and great value of my work. It encourages and motivates me to devote my full energy in my career to fight against infectious diseases. Thank you so much for believing in and supporting us as next-generation scientists with bold ideas.”
Can we harness the hidden powers of our own tissue-resident immune cells against viral infections?
FUNDED: JULY 2021
FUNDED BY: the generosity of James Isaacs
The COVID-19 pandemic underlines the urgent need to understand how our immune system protects us and find general treatments against viral infection. While antibodies and killer T cells circulating in the bloodstream have drawn the most attention for their powerful antiviral effect, there is an often overlooked but equally important part of the immune system: tissue-resident immune cells. Among them are so-called type 1 innate lymphoid cells (ILC1), which are among the first responders when a viral infection is trying to gain a foothold in the body. Due to the critical role of ILC1s, it is imperative to understand how ILC1s execute its protective function against viral infection.
In the Benedict laboratory, we have recently discovered that ILC1s can act like killer T cells, in that they can identify and destroy virus-infected cells. I want to identify and characterize the potent “weapons” ILC1s possess in their arsenal to better harness the hidden powers of ILC1s against viral infections. Most likely, ILC1s don’t use their full complement of weapons unless they encounter stressed cells, therefore I will use state of the art ‘omics’ techniques to thoroughly analyze the genes and proteins produced by ILC1 during virus infections, and identify the most powerful proteins ILC1s utilize to combat virus.
The identification of the protective function of ILC1s will deepen our understanding of how tissue-resident cells respond to emergencies and could help us better harness them for treating infectious diseases like COVID-19. Interestingly, ILCs also run constant immunosurveillance to spot and eradicate malignant cells before they can grow into a tumor. Thus a better understanding of the weapons ILC1s could also help inform new therapeutic strategies for cancers.